ES8800275A1 - Procedimiento para la preparacion de nuevos antigenos nativos pseudomonas-flagella (h) - Google Patents

Procedimiento para la preparacion de nuevos antigenos nativos pseudomonas-flagella (h)

Info

Publication number
ES8800275A1
ES8800275A1 ES550831A ES550831A ES8800275A1 ES 8800275 A1 ES8800275 A1 ES 8800275A1 ES 550831 A ES550831 A ES 550831A ES 550831 A ES550831 A ES 550831A ES 8800275 A1 ES8800275 A1 ES 8800275A1
Authority
ES
Spain
Prior art keywords
antigens
flagellar
pct
fag
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES550831A
Other languages
English (en)
Other versions
ES550831A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Immuno AG fuer Chemisch Medizinische Produkte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG, Immuno AG fuer Chemisch Medizinische Produkte filed Critical Immuno AG
Publication of ES8800275A1 publication Critical patent/ES8800275A1/es
Publication of ES550831A0 publication Critical patent/ES550831A0/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE ANTIGENOS NATIVOS PSEUDOMONAS-FLAGELLA (H). CONSISTE EN TRATAR CULTIVOS DE BACTERIAS PSEUDOMONAS AERUGINOSA, O FRACCIONES DE LOS MISMOS, CON UN DETERGENTE TAL COMO UNA SAL DEL ACIDO BILIAR, EN ESPECIAL CON OXICOLATO, PREPARACION DE LOS ANTIGENOS NATIVOS, POLIDISERSOS, DE LOS CULTIVOS; SEPARACION PREVIA DE BACTERIAS Y PARTICULAS DE BACTERIAS MEDIANTE CENTRIFUGACION; Y DEPURACION MEDIANTE TRATAMIENTO CROMATOGRAFICO. ESTOS ANTIGENOS TIENEN APLICACIONES FARMACOLOGICAS EN METODOS INMUNOLOGICOS.
ES550831A 1985-01-14 1986-01-13 Procedimiento para la preparacion de nuevos antigenos nativos pseudomonas-flagella (h) Expired ES8800275A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0007285A AT384032B (de) 1985-01-14 1985-01-14 Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)

Publications (2)

Publication Number Publication Date
ES8800275A1 true ES8800275A1 (es) 1987-11-01
ES550831A0 ES550831A0 (es) 1987-11-01

Family

ID=3480790

Family Applications (1)

Application Number Title Priority Date Filing Date
ES550831A Expired ES8800275A1 (es) 1985-01-14 1986-01-13 Procedimiento para la preparacion de nuevos antigenos nativos pseudomonas-flagella (h)

Country Status (10)

Country Link
US (1) US4831121A (es)
EP (1) EP0208743B1 (es)
JP (1) JPH085801B2 (es)
AT (2) AT384032B (es)
CA (1) CA1263307C (es)
DE (1) DE3686961D1 (es)
DK (1) DK172329B1 (es)
ES (1) ES8800275A1 (es)
FI (1) FI85221C (es)
WO (1) WO1986003974A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT391080B (de) * 1986-06-24 1990-08-10 Immuno Ag Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
US5237053A (en) * 1986-06-24 1993-08-17 Immuno Aktiengesellschaft Preparation active against Pseudomonas aeruginosa infections and methods of producing them
AT390192B (de) * 1988-08-29 1990-03-26 Immuno Ag Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobuling-h|ltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen
US4994161A (en) * 1989-02-02 1991-02-19 University Of New Hampshire Apparatus and method for macromolecular charge determination
WO2005091716A2 (en) * 2004-03-26 2005-10-06 Quark Biotech, Inc. Annexin ii and uses thereof
EP2193144A4 (en) * 2007-09-05 2012-06-27 Nurit Rachamim ANTIBODIES TO FLAGELLIN AND APPLICATIONS THEREOF
US20100239583A1 (en) * 2009-03-04 2010-09-23 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928565A (en) * 1971-10-19 1975-12-23 Yuzuru Homma Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties
JPS51133489A (en) * 1975-05-14 1976-11-19 Tokyo Daigaku Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities
FR2460139A1 (fr) * 1979-06-29 1981-01-23 Pasteur Institut Fraction antigenique glycopeptidique vaccinante a tres grande immunogenicite isolee de cultures de germes pathogenes, procedes d'isolement de cette fraction et vaccins contenant ladite fraction
US4271147A (en) * 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
EP0048422A3 (en) * 1980-09-15 1983-08-24 Bactex Incorporated Pili of pseudomonas aeruginosa and utilization of same as vaccines against infectionary p.aeruginosa
US4470924A (en) * 1981-12-30 1984-09-11 Iglewski Barbara M Nontoxic, immunologically crossreactive toxin A protein from Pseudomonas aeruginosa
US4578458A (en) * 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa

Also Published As

Publication number Publication date
EP0208743B1 (de) 1992-10-14
AT384032B (de) 1987-09-25
FI863677A0 (fi) 1986-09-11
DK421486A (da) 1986-09-03
FI85221B (fi) 1991-12-13
FI85221C (fi) 1992-03-25
FI863677A (fi) 1986-09-11
DK421486D0 (da) 1986-09-03
ATE81471T1 (de) 1992-10-15
ES550831A0 (es) 1987-11-01
CA1263307A (en) 1989-11-28
ATA7285A (de) 1987-02-15
JPH085801B2 (ja) 1996-01-24
WO1986003974A1 (en) 1986-07-17
US4831121A (en) 1989-05-16
JPS62501363A (ja) 1987-06-04
DE3686961D1 (de) 1992-11-19
EP0208743A1 (de) 1987-01-21
CA1263307C (en) 1989-11-28
DK172329B1 (da) 1998-03-23

Similar Documents

Publication Publication Date Title
Farrar et al. Biochemical relationship of thymocyte mitogenic factor and factors enhancing humoral and cell-mediated immune responses
ES2071706T3 (es) Metodo para fraccionar proteinas plasmaticas.
ES8103976A1 (es) Un metodo de producir proteinas de interferon humano de for-ma le
AU533386B2 (en) Isolation of membrane proteins from neisseria meningitidis and vaccines containing same
DK170186A (da) Biologisk ren kultur af en stamme lactobacillus acidophilus samt fremgangsmaade til isolering af en saadan kultur og anvendelse af denne somlaegemiddel
DE69032806D1 (de) Verfahren zur isolierung und reinigung von rezeptoren für transferrin und lactoferrin von bakterien und herstellung von impfstoffen, die sie enthalten
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
AU6733487A (en) Mammalian interleukin-4
ATE113654T1 (de) Follistatin und verfahren zur reinigung desselben.
Mond et al. Affinity-purified interleukin 2 induces proliferation of large but not small B cells.
DE3686954D1 (de) Loeslichkeits-, reinigungs- und charakterisierungsverfahren fuer proteine aus unloeslichen proteinaggregaten oder proteinkomplexen und diesbezuegliche praeparate.
JPS5782322A (en) Novel immunostimulant sugar protein extracted from pneumonia bacillus,obtaining method, application as drug and composition containing same
ES8800275A1 (es) Procedimiento para la preparacion de nuevos antigenos nativos pseudomonas-flagella (h)
DE3585713D1 (de) Immunoverstaerker und verfahren zu ihrer herstellung.
EP0249412A3 (en) C-terminal alpha-amidating enzyme and process for production and use thereof
EP0536564B1 (de) Verfahren zur Reinigung von Streptolysin 0, intaktes Streptolysin 0 erhältlich nach diesem Verfahren und seine Verwendung
Hong et al. Isolation and characterization of a soluble, immunoactive peptide of glial fibrillary acidic protein
Postlethwaite et al. Latent lymphokines: isolation of guinea pig latent lymphocyte-derived chemotactic factor for monocytes. Its activation by trypsin and a soluble factor from macrophages
HENSTEN‐FETTERSEN et al. Human salivary alpha‐amylase Purification and amino acid composition
DK412389D0 (da) Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning
IL72986A (en) Production of intact recombinant human immune interferon essentially free of proteolytic fragments thereof and pharmaceutical compositions containing such an interferon
JPS5767591A (en) Protein element substance and its preparation
Rey et al. The role of interleukin-2 in T colony formation by human pre-T cells (pTCFC).
Watanabe et al. Homology of partial primary sequences between α-enolase and a suppressive lymphokine from human T cells